P01
Other
CAR-NK cell therapies for treatment of severe autoimmune diseases
Marieke Arriens, Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden
P02
Other
Distinct preferences of CD8⁺ and CD4⁺ CAR-T cells for transcription factor enhancement
Fabian Freitag, Chair for Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, 97078, Germany
P03
Other
Zebrafish as a novel in vivo model to assess CAR-NK cell efficacy against metastatic breast cancer
Nivedha Murali Shankar, Technical University of Dresden, Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden, Saxony, Germany
P04
Other
Advancing antiviral siRNA therapeutics to target highly variable RNA viruses
Julian Vogler, Klinikum der Universitaet Muenchen
P05
Other
IRON: IRES launched RNA replicon for versatile and efficient gene expression
Cristian Raileanu, TRON - Translational Oncology at the University Medicine Mainz
P06
Genome editing technologies
RNAvolution in CAR-T cell therapy - Optimising RNA to generate transient CAR-T cells
Clara Gebhardt, Department of Cell and Gene Therapy Development, Fraunhofer Institute of Cell Therapy and Immunology IZI, Leipzig, 04301, Germany
P07
Genome editing technologies
An all-in-one approach for mutations in STAT3 causing Hyper-IgE-syndrome
Kerstin Geiger, Institute for Transfusion Medicine and Gene Therapy, Medical Centre - University of Freiburg, 79106 Freiburg, Germany
P08
Genome editing technologies
Generation of mRNA-based therapeutic vaccines against chronic HBV infection
Swati Singh, Institute of Virology, School of Medicine and Health, Technical University of Munich/Helmholtz Munich, 81675, Munich, Germany
P09
Genome editing technologies
A base editor mediated knock-in (BEKI) system for the non-viral generation of multiplex gene edited CAR T cells
Viktor Glaser, Charité University Medicine
P10
Genome editing technologies
UCAST: Universal detection of off-target effects of base editors
Masako Monika Kaufmann, Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, Freiburg, Germany
P11
Genome editing technologies
An ex vivo CRISPR/Cas9 based homology-directed repair gene therapy for p.W44X mutations in the HAX1 gene
Malte Ritter, University Hospital Tübingen
P12
Genome editing technologies
AAV-Mediated Prime Editing for the correction of Familial Mutations Associated with Cardiomyopathy
Vijayanand Rajendran, Klinikum rechts der Isar der TUM
P13
Genome editing technologies
Enhancing CRISPR/Cas9 Gene Therapy: Chemical Modulators for Improved Safety and Precision
Xinlai Cheng, Goethe University Frankfurt
P14
Genome editing technologies
Modulating C-to-T editing with TALE base editors
Alex Boyne, Cellectis Inc
P15
Genome editing technologies
EDSpliCE: AAV-deliverable enhanced deletion RNA-guided nucleases for therapeutic splicing modulation in USH2A
Salome Spaag, Institute for Ophthalmic Research - University Hospital Tuebingen, Germany
P16
Genome editing technologies
Design and test of a prime editor and LNPs for the CFTR F508 deletion in lung cells
Kristian Müller, Bielefeld University
P17
Genome editing technologies
VꮋH-based CLEC12A-CAR-NK cells based on llama nanobodies for treatment of Acute Myeloid Leukemia
Evelyn Ullrich, Goethe University Frankfurt
P18
Genome editing technologies
Peptide-assisted tethering of critical DNA repair effectors to Cas9 enables precise genome editing in Fanconi anemia
Sibtain Haider, Institute for Transfusion Medicine and Gene Therapy, Medical Center – University of Freiburg, Freiburg, 79106, Germany
P19
Genome editing technologies
CRISPR Therapeutic Strategy for Stargardt Disease: Correcting Exonic ABCA4:c.768G>T Mis-splicing.
Arturo Flores-Tufino, University Clinics Tübingen
P20
Genome editing technologies
Efficient Single-Base Substitution with HDR-Cas9: A Step Towards Sickle Cell Disease Cure
Ali Faiq, Freiburg University
P21
Genome editing technologies
Developing Designer-Recombinase induced Gene Replacement (DRiGR) with clinical implications
ZiXi (Mike) Dai, Technical University of Dresden
P23
Delivery
Towards a prime-boost vaccine platform based on different adenovirus types
Hannes Schmietendorf, Ulm University
P24
Delivery
AAV's next top model: Influence of animal species on directed evolution of myotropic AAV capsids
Kristian Leite, University of Heidelberg
P25
Delivery
CAPSULON: The Next Step in Efficient and Safe siRNA Delivery for Clinical Applications and Gene Therapy
Iana Tarakanchikova, CapCoBIO GmbH, 79106 Freiburg im Breisgau, Germany
P26
Delivery
Bypassing ex vivo CAR T cell manufacturing: leveraging LNPs for in vivo delivery
Ela Cetin, Department of Cell and Gene Therapy Development, Fraunhofer Institute of Cell Therapy and Immunology IZI, Leipzig, 04301, Germany
P27
Delivery
Versatile lipid nanoparticle platform for efficient CRISPR-Cas9 gene editing in primary T cells and CD34+ hematopoietic stem cells
Martin Rabel, Cytiva, 655 W Kent Ave N, Vancouver, BC, V6P 6T3, Canada
P28
Crispr Screens
Genome-Scale CRISPR/Cas9 screening in tumor cells to identify mechanisms for overcoming cancer resistance in NK cell-based immunotherapy
Maria Schuldt, Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
P29
Clinics
Shortened Half-Life Sleeping Beauty Transposase for Biosafety-Enhanced CAR-T Cell Production
Tamás Raskó, Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II Lehrstuhl für Zelluläre Immuntherapie Würzburg 97078 Germany
P30
Clinics
FindMe2care – a contact platform for patients with genetically confirmed diagnoses
Christian Gebhard, MGZ Medizinisch Genetisches Zentrum, Munich